Liquidia Corporation (LQDA) Financial Analysis & Valuation | Quarter Chart
Liquidia Corporation (LQDA)
LQDAPrice: $75.12
Fair Value: 🔒
🔒score
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension... more
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes variou... more
Description
Shares
| Market Cap | $6.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Roger A. Jeffs |
| IPO Date | 2018-07-26 | CAGR | 0.32% |
| Employees | 170 | Website | www.liquidia.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LQDA chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.62B | P/E Ratio | 536.57 |
| Forward P/E | 13.48 | PEG Ratio | — |
| P/S Ratio | 29.93 | P/B Ratio | 78.55 |
| P/CF Ratio | 177.75 | P/FCF Ratio | 209.47 |
| EPS | $0.14 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1936.66% | Gross Margin | 0.92% |
| Operating Margin | 0.16% | Profit Margin | 0.08% |
| ROE | 0.47% | ROA | 0.06% |
| ROCE | 0.18% | Current Ratio | 2.22 |
| Quick Ratio | 2.03 | Cash Ratio | 1.49 |
| Debt/Equity | 1.7 | Interest Coverage | 1.75 |
| Altman Z Score | 13.52 | Piotroski Score | 6 |